Pulmonary Arterial Hypertension


Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.

Related Articles


Pulmonary Hypertension in Heart Failure Patients

Sriram D Rao, Srinath Adusumalli, Jeremy A Mazurek,

Citation: Cardiac Failure Review 2020;6:e05.

Long-term Outcome of Pulmonary Vein Isolation Versus Amiodarone Therapy in…

Michela Faggioni, Domenico G Della Rocca, Sanghamitra Mohanty,

Citation: Cardiac Failure Review 2020;6:e04.

Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase…

Hiroshi Watanabe,

Citation: European Cardiology Review 2018;13(1):35–7.

Recognition, Diagnosis, and Management of Heart Failure with Preserved…

Meshal Soni, Edo Y Birati,

Citation: US Cardiology Review 2018;12(1):8–12.